Bennett Lawrence Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Bennett Lawrence Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$1.71M	Buy	38,850 +4,050	+12%	+$201K	0.55%	62
2015 Q3	$1.42M	Buy	34,800 +7,850	+29%	+$344K	0.45%	60
2015 Q2	$1.44M	Sell	26,950 -3,050	-10%	-$162K	0.38%	65
2015 Q1	$1.82M	Buy	+30,000	New	+$1.46M	0.49%	57

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bennett Lawrence Management's JUNO Position: Q4 2015 in Review

Bennett Lawrence Management increased its Juno Therapeutics, Inc. (JUNO) stake by 12% in Q4 2015, buying an estimated $201K and bringing the position to 38,850 shares worth $1.71M. The position accounts for 0.55% of the portfolio, ranked #62.

Bennett Lawrence Management first reported a position in JUNO in Q1 2015 and has held it in 4 quarters since. The position peaked at $1.82M in Q1 2015. 160 funds tracked by Wall St. Rank hold JUNO as of Q4 2015.

Bennett Lawrence Management held 38,850 shares of Juno Therapeutics, Inc. worth $1.71M as of Q4 2015.
Bennett Lawrence Management bought 4,050 Juno Therapeutics, Inc. shares in Q4 2015, an estimated $201K.
Juno Therapeutics, Inc. made up 0.55% of Bennett Lawrence Management's portfolio in Q4 2015, its #62 holding.
Bennett Lawrence Management first reported a position in Juno Therapeutics, Inc. in Q1 2015 and has held it in 4 quarters since.
Bennett Lawrence Management's Juno Therapeutics, Inc. position peaked at $1.82M in Q1 2015.
160 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q4 2015.

Based on Bennett Lawrence Management's 13F filing for Q4 2015, filed 16 Feb 2016.